Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas

Wenhua Piao, Yu Wang, Yasushi Adachi, Hiroyuki Yamamoto, Rong Li, Arisa Imsumran, Hua Li, Tadateru Maehata, Masanori Ii, Yoshiaki Arimura, Choon Taek Lee, Yasuhisa Shinomura, David P. Carbone, Kohzoh Imai

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Insulin-like growth factor-I receptor (IGF-IR) signaling is required for carcinogenicity and proliferation of gastrointestinal (GI) cancers. In this study, we sought to evaluate the effect of a new tyrosine kinase inhibitor of IGF-IR, NVP-AEW541, on the signal transduction and the progression of GI carcinomas. We assessed the effect of NVP-AEW541 on signal transduction, proliferation, survival, and migration in four GI cancer cells: colorectal adenocarcinoma HT29, pancreatic adenocarcinoma BxPC3, esophageal squamous cell carcinoma TE1, and hepatoma PLC/PRF/5. The effects of NVP-AEW541 alone and with chemotherapy were studied in vitro and in nude mouse xenografts. We also analyzed the effects of NVP-AEW541 on insulin signals and hybrid receptor formation between IGF-IR and insulin receptor. NVP-AEW541 blocked autophosphorylation of IGF-IR and both Akt and extracellular signal-regulated kinase activation by IGF but not by insulin. NVP-AEW541 suppressed proliferation and tumorigenicity in vitro in a dose-dependent manner in all cell lines. The drug inhibited tumor as a single agent and, when combined with stressors, up-regulated apoptosis in a dose-dependent fashion and inhibited mobility. NVP-AEW541 augmented the effects of chemotherapy on in vitro growth and induction of apoptosis. Moreover, the combination of NVP-AEW541 and chemotherapy was highly effective against tumors in mice. This compound did not influence hybrid receptor formation. Thus, NVP-AEW541 may have significant therapeutic utility in human GI carcinomas both alone and in combination with chemotherapy.

Original languageEnglish
Pages (from-to)1483-1493
Number of pages11
JournalMolecular Cancer Therapeutics
Volume7
Issue number6
DOIs
Publication statusPublished - 2008
Externally publishedYes

Fingerprint

IGF Type 1 Receptor
Protein-Tyrosine Kinases
Carcinoma
Gastrointestinal Neoplasms
Drug Therapy
Signal Transduction
Adenocarcinoma
Insulin
Apoptosis
NVP-AEW541
Insulin Receptor
Extracellular Signal-Regulated MAP Kinases
Combination Drug Therapy
Heterografts
Nude Mice
Hepatocellular Carcinoma
Neoplasms
Cell Line
Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Drug Discovery
  • Pharmacology

Cite this

Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas. / Piao, Wenhua; Wang, Yu; Adachi, Yasushi; Yamamoto, Hiroyuki; Li, Rong; Imsumran, Arisa; Li, Hua; Maehata, Tadateru; Ii, Masanori; Arimura, Yoshiaki; Lee, Choon Taek; Shinomura, Yasuhisa; Carbone, David P.; Imai, Kohzoh.

In: Molecular Cancer Therapeutics, Vol. 7, No. 6, 2008, p. 1483-1493.

Research output: Contribution to journalArticle

Piao, W, Wang, Y, Adachi, Y, Yamamoto, H, Li, R, Imsumran, A, Li, H, Maehata, T, Ii, M, Arimura, Y, Lee, CT, Shinomura, Y, Carbone, DP & Imai, K 2008, 'Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas', Molecular Cancer Therapeutics, vol. 7, no. 6, pp. 1483-1493. https://doi.org/10.1158/1535-7163.MCT-07-2395
Piao, Wenhua ; Wang, Yu ; Adachi, Yasushi ; Yamamoto, Hiroyuki ; Li, Rong ; Imsumran, Arisa ; Li, Hua ; Maehata, Tadateru ; Ii, Masanori ; Arimura, Yoshiaki ; Lee, Choon Taek ; Shinomura, Yasuhisa ; Carbone, David P. ; Imai, Kohzoh. / Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas. In: Molecular Cancer Therapeutics. 2008 ; Vol. 7, No. 6. pp. 1483-1493.
@article{73f58558f1114ea19386f8e6f54823c3,
title = "Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas",
abstract = "Insulin-like growth factor-I receptor (IGF-IR) signaling is required for carcinogenicity and proliferation of gastrointestinal (GI) cancers. In this study, we sought to evaluate the effect of a new tyrosine kinase inhibitor of IGF-IR, NVP-AEW541, on the signal transduction and the progression of GI carcinomas. We assessed the effect of NVP-AEW541 on signal transduction, proliferation, survival, and migration in four GI cancer cells: colorectal adenocarcinoma HT29, pancreatic adenocarcinoma BxPC3, esophageal squamous cell carcinoma TE1, and hepatoma PLC/PRF/5. The effects of NVP-AEW541 alone and with chemotherapy were studied in vitro and in nude mouse xenografts. We also analyzed the effects of NVP-AEW541 on insulin signals and hybrid receptor formation between IGF-IR and insulin receptor. NVP-AEW541 blocked autophosphorylation of IGF-IR and both Akt and extracellular signal-regulated kinase activation by IGF but not by insulin. NVP-AEW541 suppressed proliferation and tumorigenicity in vitro in a dose-dependent manner in all cell lines. The drug inhibited tumor as a single agent and, when combined with stressors, up-regulated apoptosis in a dose-dependent fashion and inhibited mobility. NVP-AEW541 augmented the effects of chemotherapy on in vitro growth and induction of apoptosis. Moreover, the combination of NVP-AEW541 and chemotherapy was highly effective against tumors in mice. This compound did not influence hybrid receptor formation. Thus, NVP-AEW541 may have significant therapeutic utility in human GI carcinomas both alone and in combination with chemotherapy.",
author = "Wenhua Piao and Yu Wang and Yasushi Adachi and Hiroyuki Yamamoto and Rong Li and Arisa Imsumran and Hua Li and Tadateru Maehata and Masanori Ii and Yoshiaki Arimura and Lee, {Choon Taek} and Yasuhisa Shinomura and Carbone, {David P.} and Kohzoh Imai",
year = "2008",
doi = "10.1158/1535-7163.MCT-07-2395",
language = "English",
volume = "7",
pages = "1483--1493",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas

AU - Piao, Wenhua

AU - Wang, Yu

AU - Adachi, Yasushi

AU - Yamamoto, Hiroyuki

AU - Li, Rong

AU - Imsumran, Arisa

AU - Li, Hua

AU - Maehata, Tadateru

AU - Ii, Masanori

AU - Arimura, Yoshiaki

AU - Lee, Choon Taek

AU - Shinomura, Yasuhisa

AU - Carbone, David P.

AU - Imai, Kohzoh

PY - 2008

Y1 - 2008

N2 - Insulin-like growth factor-I receptor (IGF-IR) signaling is required for carcinogenicity and proliferation of gastrointestinal (GI) cancers. In this study, we sought to evaluate the effect of a new tyrosine kinase inhibitor of IGF-IR, NVP-AEW541, on the signal transduction and the progression of GI carcinomas. We assessed the effect of NVP-AEW541 on signal transduction, proliferation, survival, and migration in four GI cancer cells: colorectal adenocarcinoma HT29, pancreatic adenocarcinoma BxPC3, esophageal squamous cell carcinoma TE1, and hepatoma PLC/PRF/5. The effects of NVP-AEW541 alone and with chemotherapy were studied in vitro and in nude mouse xenografts. We also analyzed the effects of NVP-AEW541 on insulin signals and hybrid receptor formation between IGF-IR and insulin receptor. NVP-AEW541 blocked autophosphorylation of IGF-IR and both Akt and extracellular signal-regulated kinase activation by IGF but not by insulin. NVP-AEW541 suppressed proliferation and tumorigenicity in vitro in a dose-dependent manner in all cell lines. The drug inhibited tumor as a single agent and, when combined with stressors, up-regulated apoptosis in a dose-dependent fashion and inhibited mobility. NVP-AEW541 augmented the effects of chemotherapy on in vitro growth and induction of apoptosis. Moreover, the combination of NVP-AEW541 and chemotherapy was highly effective against tumors in mice. This compound did not influence hybrid receptor formation. Thus, NVP-AEW541 may have significant therapeutic utility in human GI carcinomas both alone and in combination with chemotherapy.

AB - Insulin-like growth factor-I receptor (IGF-IR) signaling is required for carcinogenicity and proliferation of gastrointestinal (GI) cancers. In this study, we sought to evaluate the effect of a new tyrosine kinase inhibitor of IGF-IR, NVP-AEW541, on the signal transduction and the progression of GI carcinomas. We assessed the effect of NVP-AEW541 on signal transduction, proliferation, survival, and migration in four GI cancer cells: colorectal adenocarcinoma HT29, pancreatic adenocarcinoma BxPC3, esophageal squamous cell carcinoma TE1, and hepatoma PLC/PRF/5. The effects of NVP-AEW541 alone and with chemotherapy were studied in vitro and in nude mouse xenografts. We also analyzed the effects of NVP-AEW541 on insulin signals and hybrid receptor formation between IGF-IR and insulin receptor. NVP-AEW541 blocked autophosphorylation of IGF-IR and both Akt and extracellular signal-regulated kinase activation by IGF but not by insulin. NVP-AEW541 suppressed proliferation and tumorigenicity in vitro in a dose-dependent manner in all cell lines. The drug inhibited tumor as a single agent and, when combined with stressors, up-regulated apoptosis in a dose-dependent fashion and inhibited mobility. NVP-AEW541 augmented the effects of chemotherapy on in vitro growth and induction of apoptosis. Moreover, the combination of NVP-AEW541 and chemotherapy was highly effective against tumors in mice. This compound did not influence hybrid receptor formation. Thus, NVP-AEW541 may have significant therapeutic utility in human GI carcinomas both alone and in combination with chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=49849098247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49849098247&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-07-2395

DO - 10.1158/1535-7163.MCT-07-2395

M3 - Article

VL - 7

SP - 1483

EP - 1493

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 6

ER -